XENE | Ticker Profile - Titan Protect

XENE

Xenon Pharmaceuticals Inc.

Healthcare · Biotechnology · NGM

$51.73

Data: 2026-05-28

✗ ETHICAL FAIL

Unknown MOAT

MODERATE

Data Confidence: 71.4%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$5.2B

Total market value of the company

Trailing P/E

N/A

Forward P/E

-10.76

Based on estimated future earnings — lower means cheaper

Rev Growth

N/A

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

-37.5%

Return on equity — how efficiently it uses shareholder money

Analyst Target

$80.00

+55% from current price — median analyst estimate

Recommendation

STRONG_BUY

Consensus view from 19 analysts covering this stock

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

https://www.xenon-pharma.com

Country: Canada Employees: 358 Industry: Biotechnology

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

0.0% N/A

Debt must be below 33% of total assets

Cash Ratio

0.0% N/A

Interest-bearing cash below 33% of assets

Receivables

0.0% N/A

Receivables below 49% of assets

Revenue Purity

0.0% N/A

Non-compliant revenue below 5% — any excess requires purification

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKDOWN

Price trending down — defensive positioning

Sharpe Ratio

0.580

Good returns relative to risk taken

Kelly Fraction

0.0563

Suggested allocation is meaningful — the edge justifies a position

Calmar Ratio

0.516

Acceptable balance between returns and drawdown risk

Annual Return

19.8%

Historical annualised return based on price data

Max Drawdown

-38.3%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

0.65

Less volatile than the market — more defensive

52W High

$63.95

19% below the year high

52W Low

$28.19

84% above the year low

Avg Volume

1,456,539

Average daily shares traded — higher means easier to buy and sell

Short Ratio

4.1

Days it would take all short sellers to cover — higher means more crowded

Short % Float

4.0%

Low short interest — limited bearish positioning

Div Yield

N/A

Annual dividend as a percentage of the share price

EPS (TTM)

$-4.70

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

0.56

Moderate leverage — manageable

Current Ratio

27.79

Strong balance sheet — comfortably covers short-term obligations

Quick Ratio

27.53

Like current ratio but excludes inventory — stricter test

Gross Margin

0.0%

Revenue left after cost of goods — higher means pricing power

Operating Margin

0.0%

Profit from core operations before interest and tax

Free Cash Flow

$-186,274,496

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

$-383,164,992

Loss-making — spending exceeds revenue after all costs

Analyst Coverage

Analysts

Target High

$100.00

Target Median

$80.00

Target Low

$56.00

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-28

Before you go